Vaxxinova Brasil will take part in another edition of the International Animal Protein Show (SIAVS), which will be held from August 6 to 8 in São Paulo. At the booth, visitors will be able to explore a diverse portfolio with customized solutions for poultry, cattle, fish and swine production, including the new Vaxxon Sa lb + III solution, focused on the prevention of Streptococcus agalactiae in freshwater fish, a disease that causes significant losses to the market.
“As a company, we are committed to offering solutions that provide greater safety and peace of mind to our customers, and this new launch is designed precisely to achieve that, improving the immune response of animals raised in Brazil, increasing flock protection levels and ensuring greater confidence for producers,” explains Rodrigo Pedralli, Aqua Business Manager.
Another product launch that will also be highlighted during the trade fair is Treoxin Bovinos, a macrolide antibiotic from the triamilide group. The product reflects Vaxxinova’s commitment to delivering solutions that not only treat diseases, but also promote sustainable and responsible practices in modern cattle production. Leydson Martins notes that Brazilian cattle farming has been significantly shortening the production cycle by using feedlots as a nutritional strategy to slaughter younger animals, resulting in better beef quality. In line with this trend, the company decided to expand its portfolio with a focus on feedlot entry protocols, launching the new product. “Treoxin Bovinos has a formulation based on 10 percent Tulathromycin for single dose subcutaneous application. It was developed in accordance with the highest standards of food safety and animal welfare, and its main use is to combat bovine respiratory diseases, although it is also indicated for hoof treatments and infectious bovine keratoconjunctivitis,” explains Martins.
Development and Commitment
Commitment to agribusiness is a defining characteristic of Vaxxinova, and during SIAVS 2024 the company will reinforce its dedication to innovation and adaptation to the specific needs of each customer, standing out as a reference in the agribusiness sector. According to Jeovane Pereira, Director of Poultry Business, the event will be an important opportunity for the Vaxxinova team. “We are continuously expanding and bringing in new professionals to keep delivering the best to our customers who trust our products, such as Vaxxon Coccivet, which will be one of our highlights,” says the director.
Product Manager Jeniffer Pimenta emphasizes that the concept of vaccination for long cycle poultry in Brazil is well established. “The Vaxxon Coccivet R vaccine has been a market leader for 19 years, with measurable results in preventing coccidiosis in long cycle poultry. This year, we launched the same concept for coccidiosis control with the Vaxxon Coccivet vaccine, aimed at the broiler market, focusing on biological control and poultry immunology. The importance of the live attenuated vaccine for broiler farms aligns with the growth of the poultry industry. The use of Vaxxon Coccivet through spray vaccination on the first day effectively immunizes birds and improves intestinal quality, contributing to better zootechnical performance,” adds the manager.
In addition to innovations in the poultry sector, Vaxxinova has also been making large scale investments in its Swine Business Unit. Govaxx autogenous vaccines for the prevention of respiratory bacterial problems already hold a leading position in this market. According to Rogério Petri, Swine Business Unit Manager, the company will soon expand its portfolio, considering that the Brazilian pork market, currently the world’s fourth largest producer and exporter, is expected to reach third place by the end of 2024, according to ABPA. “The Swine Business Unit is crucial to Vaxxinova’s growth. We are committed to strengthening our market position through advances in research and development, seeking innovative solutions to increase productivity and sustainability in swine production,” says Rogério Petri.
About Vaxxinova
Vaxxinova, a Dutch company that is part of the German EW Group, a family owned holding specialized in genetics, animal health and nutrition, has been operating in Brazil since 2018, when it acquired Laboratório Biovet, which had been active in the Brazilian and Latin American animal health market since 1957.
Headquartered in Vargem Grande Paulista, the company specializes in disease prevention for production animals, as well as pet care and longevity. Vaxxinova operates in more than 50 countries and is headquartered in Nijmegen, the Netherlands, with research centers and production and diagnostic facilities in locations such as Germany, Italy, Norway, Japan, Jordan, the Netherlands, the United States and Brazil.
